Gammaked Background

General CIDP Information


Chronic inflammatory demyelinating polyneuropathy (or polyradiculoneuropathy), is the most commonly acquired demyelinating neuropathy. CIDP is an autoimmune disorder whereby autoantibodies attack and destroy the myelin sheath of the peripheral nerves.It can commonly present either as a continuously progressive affliction or less often, as a recurrent disorder in which episodes (relapsing and remitting) in individual patients may be separated by months or years.

The etiology remains unknown and CIDP remains a syndrome with several variants, primarily defined by differences in clinical presentation. The classification is still debated, but virtually all neurologists define the disorder as being chronic (> 8 weeks progression), demyelinating, and inflammatory or immune-mediated.



CIDP is the most commonly acquired demyelinating neuropathy. The exact prevalence of CIDP is unclear but, in studies performed worldwide, it has been estimated to range from 1.9 per 100,000 to 7.7 per 100,000.2,3

Although the exact cause is not known, CIDP is considered an autoimmune disorder. Symptoms are caused by damage to the myelin sheath in the peripheral nerves. 



Symptoms of CIDP vary from mild to debilitating and patients may have atypical presentations.

Signs of CIDP may include4:

  • Symmetrical proximal and distal motor and sensory loss
  • Loss of deep tendon reflexes in affected extremities
  • Clinical course progressing for more than 2 months
  • Fatigue and pain in extremities



The cause of CIDP is not known. As a syndrome, different causes and triggers are likely. However, it is generally accepted that most, if not all, CIDP manifestations are autoimmune, triggered by infections or toxins in genetically susceptible individuals. The autoimmune nature of CIDP is suspected because of its occasional association with other immune-mediated diseases, such as systemic lupus, hepatitis B and C, HIV and multiple sclerosis (MS), its response to immunosuppressive and immunomodulatory treatments, and pathologic findings on nerve biopsy. Other causes of neuropathy that may be difficult to distinguish from CIDP include:

  • Inherited neuropathy
  • Systemic inflammatory-autoimmune disorders
  • Dysproteinemias
  • Diabetes mellitus
  • Vasculitis
  • Other metabolic and toxic neuropathies



The most common adverse reactions observed at a rate ≥ 5% in subjects with Gammaked for CIDP were headache, fever, chills, hypertension, rash, nausea and asthenia.5


References1. Latov N. Diagnosis of CIDP. Neurology. 2002;59(12 suppl 6):S2-6. 2. McLeod JG, Pollard JD, Macaskill P, et al. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol. 1999;46(6)910-913. 3. Mygland A, Monstad P. Chronic polyneuropathies in Vest-Agder, Norway. Eur J Neurol. 2001;8(2):157-165. 4. Köller H, Kieseier BC, Jander S, Hartung HP. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med. 2005;352(13):1343-1356. 5. GAMMAKED [package insert]. Fort Lee, NJ. Kedrion Biopharma Inc., 2013.